— Know what they know.
Not Investment Advice

RPRX NASDAQ

Royalty Pharma plc
1W: +2.5% 1M: +7.4% 3M: +18.9% YTD: +51.9% 1Y: +62.4% 3Y: +102.0% 5Y: +64.1%
$59.97
+1.24 (+2.11%)
 
Weekly Expected Move ±4.1%
$54 $56 $59 $61 $64
NASDAQ · Healthcare · Medical - Pharmaceuticals · Alpha Radar Strong Buy · Power 69 · $25.8B mcap · 414M float · 0.908% daily turnover · Short 32% of daily vol
Smart Money Score
Watch 25
Insider
Congress
ETF Holdings
Key Statistics
Market Cap$25.8B
52W Range34.081-60.08
Volume3,026,000
Avg Volume3,754,875
Beta0.42
Dividend$0.91
Analyst Ratings
11 Buy 0 Hold 0 Sell
Consensus Buy
Company Info
CEOPablo Legorreta
Employees100
SectorHealthcare
IndustryMedical - Pharmaceuticals
IPO Date2020-06-16
110 East 59th Street
New York, NY 10022
US
212 883 0200
About Royalty Pharma plc

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Recent Insider Trades

NameTypeSharesPriceDate
Urist Marshall S-Sale 9,099 $55.88 2026-07-01
Bassler Bonnie L A-Award 689 $54.40 2026-06-30
Urist Marshall S-Sale 9,098 $55.18 2026-06-24
Hite Christopher S-Sale 32,408 $54.11 2026-06-23
Hite Christopher S-Sale 117,592 $54.47 2026-06-23

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms